Emerging therapeutic agents for advanced non-small cell lung cancer

Ruqin Chen, Rami Manochakian, Lauren James, Abdel Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou, Yanyan Lou

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.

Original languageEnglish (US)
Article number58
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - May 24 2020


  • Advanced non-small cell lung cancer
  • Clinical trials
  • Emerging therapeutic agents
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Emerging therapeutic agents for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this